Viridis Pharmaceutical v. EUIPO, Case No. C-668/17 (July 3, 2019)
Viridis Pharmaceutical Ltd.’s (Viridis) use of BOSWELAN in connection with clinical trials for a drug to treat multiple sclerosis was held to be insufficient evidence of genuine use to defeat a non-use cancellation action against its EUTM registration for pharmaceutical and healthcare products.More
















































